Business
Phase 1a clinical trial for SDC-1801
Phase 1a clinical trial for SDC-1801.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\n Sareum Holdings PLC\n(\"Sareum\" or the \"Company\")\nSareum announces the commencement of a Phase 1a clinical trial for SDC-1801\nCambridge, UK, 18 May 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the initiation of a Phase 1a clinical trial for its lead product SDC-1801. The trial has started with patient recruitment in progress at specialist clinical units located in Victoria, Australia.\nSDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.\nThis follows the recent approval of the Company's application under the Clinical Trial Notification (CTN) scheme by the Human Research Ethics Committee (HREC). Australia's medicines regulator, the Therapeutic Goods Administration (TGA), has also acknowledged the application, allowing for the Phase 1a trial to proceed.\nThe initial Phase 1a trial is designed to investigate the safety and pharmacokinetics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p). Provided satisfactory safety data are obtained from this initial study, a Phase 1b clinical study is expected to commence in psoriasis patients in 2024.\n-Ends-\nFor further information, please contact: \n\n\n\nSareum Holdings plc\nTim Mitchell, CEO\nLauren Williams, Head of Investor Relations\n\n\n \n01223 497700\[email protected]\n \n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Dance / James Bellman\n \n\n\n \n020 7409 3494\n\n\n\n\nPeel Hunt LLP (Joint Corporate Broker)\nJames Steel / Oliver Duckworth\n \n\n\n \n020 7418 8900\n\n\n\n\nHybridan LLP (Joint Corporate Broker)\nClaire Noyce\n \n\n\n \n020 3764 2341\n\n\n\n\nConsilium Strategic Communications (Financial PR)\nJessica Hodgson / Davide Salvi / Stella Lempidaki\n \n \n\n\n \n020 3709 5700\n\n\n\nAbout Sareum\nSareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.\nThe Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class po...